Ronac Mamtani, MD, MSCE
Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-308
3400 Civic Center Blvd
Philadelphia, PA 19147
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-308
3400 Civic Center Blvd
Philadelphia, PA 19147
Office: 2156627606
Fax: (215) 349-8551
Fax: (215) 349-8551
Email:
ronac.mamtani@uphs.upenn.edu
ronac.mamtani@uphs.upenn.edu
Education:
BS
Cornell University, 2002.
MD (Internal Medicine)
Stony Brook School of Medicine, 2006.
MS (Clinical Epidemiology)
University of Pennsylvania , 2012.
Permanent linkBS
Cornell University, 2002.
MD (Internal Medicine)
Stony Brook School of Medicine, 2006.
MS (Clinical Epidemiology)
University of Pennsylvania , 2012.
Selected Publications
Lian Y, Voruganti T, Lu J, Long Q, Mamtani R.: Survival Trends in Urothelial Cancer Before and After ICIs and Antibody Drug Conjugates. JAMA Netw Open 8: e2519524, Jul 2025.Reibel JB, Sun LL, Parikh RB, Mahmud N, Martin LP, Hubbard RA, Mamtani R.: Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer. J Natl Cancer Inst 117: 1276-1278, Jun 2025.
Swami N, Hwang WT, Mamtani R, O'Hara MH, Chapin WJ.: Second-Line Treatment Strategies for Right-Sided, RAS/RAF Wild-Type Colorectal Cancer. JAMA Netw Open 8: e2515087, Jun 2025.
Kurian M, Nimgaonkar V, Elghawy O, Mamtani R.: Real-world enfortumab vedotin +/- pembrolizumab (EV+/-P)–based treatment toxicity, treatment discontinuation, and associations with survival in advanced urothelial carcinoma (aUC). American Society of Clinical Oncology Annual Meeting I 2025, Chicago, IL. 43(16), May 2025.
Kurian M, Ferrell WJ, Ulloa Perez E, Hubbard R, Joffe S, Mamtani R, Parikh RB, Lynch HF.: Specificity of Food and Drug Administration postmarketing requirements and associations with timely submissions and regulatory decisions for oncology accelerated approvals, 2011-2023: a cross-sectional analysis. BMJ Oncol 4: e000659, May 2025.
Wang X, Long JB, Rothen J, Huang S, Soulos P, Robinson TJ, Presley CJ, Goldberg SB, Mamtani R, Ma SM, Wang SY, Dinan MA, Gross CP. : Use of targeted therapy in patients with advanced non-small cell lung cancer in response to broad genomic profiling. American Society of Clinical Oncology Annual Meeting I 2025, Chicago IL. 43(16), May 2025.
Wang X, Rothen J, Huang S, Long JB, Soulos PR, Goldberg SB, Mamtani R, Presley CJ, Kunst N, Ma S, Wang SY, Gross CP, Dinan MA.: Adoption of Broad Genomic Profiling in Patients With Cancer. JAMA Oncol Apr 2025.
Wang X, Long JB, Rothen J, Soulos PR, Robinson TJ, Presley CJ, Goldberg SB, Mamtani R, Wang SY, Kunst N, Ma S, Huang S, Gross CP, Dinan MA.: BPI25-017: A Novel Integrated Classification Schema for Molecular Findings by Potential Clinical Actionability: A Tool for Assessment of Real-World Cancer Care in the Targeted Therapy Era. J Natl Compr Canc Netw 23, Mar 2025.
Geynisman DM, Chepynoga K, Yates G, Tate A, Kurt M, Patel MY, Teitsson S, Mitra S, Mamtani R.: Estimating the Impact of Adjuvant Treatment With Nivolumab on Long-Term Survivorship Rates Compared With Surveillance in Muscle Invasive Urothelial Carcinoma: Mixture Cure Modeling Analyses of Disease-Free Survival From the Phase 3 CheckMate 274 Trial. Clin Genitourin Cancer Mar 2025.
Barsouk A, Elghawy O, Sussman JH, Xu J, Mamtani R, Mei L.: Survival disparities by sex with contemporary advanced urothelial carcinoma (aUC) therapy: A real-world analysis. American Society of Clinical Oncology Genitourinary Cancers Symposium 2025, San Fran, CA. 43(5), Feb 2025.